Literature DB >> 20094738

Oxidative stress and plasma aminopeptidase activity in Huntington's disease.

Raquel Duran1, Francisco J Barrero, Blas Morales, Juan D Luna, Manuel Ramirez, Francisco Vives.   

Abstract

Huntington's disease (HD) is a genetic neurodegenerative disorder. Oxidative stress, mitochondrial dysfunction, and protein metabolism impairment have been implicated in its pathogenesis. However, the contribution of these phenomena to HD onset or progression is not well known, and they have been less studied in peripheral blood. We analyzed plasma lipid peroxide (LPO) and lactate (LAC) concentrations as indicators of oxidative stress and mitochondrial dysfunction in symptomatic HD patients (sHD) and asymptomatic HD gene carriers (aHD). We also measured the plasma activity of aminopeptidases (APs), an important group of proteolytic enzymes. LPO and LAC concentrations were significantly elevated in sHD patients but not in aHD carriers. Aspartate and glutamate AP activities were significantly reduced in sHD patients and aHD carriers. These findings demonstrate that sHD patients are under oxidative stress, which may favor progression of the disease. Plasma AP activity was decreased before the appearance of HD symptoms and oxidative stress and may be related to protein metabolism impairment. These results indicate that therapy directed to improve oxidative stress and normalize AP activity may be useful in the treatment of HD. They also suggest that decreased plasma AP activity in aHD carriers may predict the future onset of HD symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20094738     DOI: 10.1007/s00702-009-0364-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  36 in total

1.  Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.

Authors:  B G Jenkins; W J Koroshetz; M F Beal; B R Rosen
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

2.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.

Authors:  Carsten Saft; Jochen Zange; Jürgen Andrich; Klaus Müller; Katrin Lindenberg; Bernhard Landwehrmeyer; Matthias Vorgerd; Peter H Kraus; Horst Przuntek; Ludger Schöls
Journal:  Mov Disord       Date:  2005-06       Impact factor: 10.338

3.  Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation.

Authors:  N Bhutani; P Venkatraman; A L Goldberg
Journal:  EMBO J       Date:  2007-02-22       Impact factor: 11.598

Review 4.  Brain aminopeptidases and hypertension.

Authors:  Inmaculada Banegas; Isabel Prieto; Francisco Vives; Francisco Alba; Marc de Gasparo; Ana Belen Segarra; Francisco Hermoso; Raquel Durán; Manuel Ramírez
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2006-09       Impact factor: 1.636

Review 5.  Brain-specific aminopeptidase: from enkephalinase to protector against neurodegeneration.

Authors:  Koon-Sea Hui
Journal:  Neurochem Res       Date:  2007-05-03       Impact factor: 3.996

6.  Use of capillary electrophoresis for accurate determination of CAG repeats causing Huntington disease. An oligonucleotide design avoiding shadow bands.

Authors:  Sonia Blanco; Antonio Suarez; Sandra Gandia-Pla; Carolina Gómez-Llorente; Adelaida Antúnez; Jose Antonio Gómez-Capilla; M Esther Fárez-Vidal
Journal:  Scand J Clin Lab Invest       Date:  2008       Impact factor: 1.713

7.  A continuous fluorimetric assay for aminopeptidase P detailed analysis of product inhibition.

Authors:  Angela Stöckel-Maschek; Beate Stiebitz; Regine Koelsch; Klaus Neubert
Journal:  Anal Biochem       Date:  2003-11-01       Impact factor: 3.365

8.  Mitochondrial defect in Huntington's disease caudate nucleus.

Authors:  M Gu; M T Gash; V M Mann; F Javoy-Agid; J M Cooper; A H Schapira
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

9.  Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction.

Authors:  Anand Goswami; Priyanka Dikshit; Amit Mishra; Shalaka Mulherkar; Nobuyuki Nukina; Nihar Ranjan Jana
Journal:  Biochem Biophys Res Commun       Date:  2006-02-03       Impact factor: 3.575

10.  Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.

Authors:  D Dawbarn; N Zamir; C M Waters; S P Hunt; P C Emson; M J Brownstein
Journal:  Brain Res       Date:  1986-04-30       Impact factor: 3.252

View more
  8 in total

1.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 2.  The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review.

Authors:  Shanmugam Manoharan; Gilles J Guillemin; Rajagopal Selladurai Abiramasundari; Musthafa Mohamed Essa; Mohammed Akbar; Mohammed D Akbar
Journal:  Oxid Med Cell Longev       Date:  2016-12-27       Impact factor: 6.543

Review 3.  Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases.

Authors:  Julia Konovalova; Dmytro Gerasymchuk; Ilmari Parkkinen; Piotr Chmielarz; Andrii Domanskyi
Journal:  Int J Mol Sci       Date:  2019-11-30       Impact factor: 5.923

4.  Protection by glia-conditioned medium in a cell model of Huntington disease.

Authors:  Carolina Ruiz; Maria Jose Casarejos; Ana Gomez; Rosa Solano; Justo Garcia de Yebenes; Maria Angeles Mena
Journal:  PLoS Curr       Date:  2012-07-02

5.  Redox processes in neurodegenerative disease involving reactive oxygen species.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

6.  Blood Oxidative Stress Marker Aberrations in Patients with Huntington's Disease: A Meta-Analysis Study.

Authors:  Quan Tang; Hua Liu; Xiao-Jie Shi; Yong Cheng
Journal:  Oxid Med Cell Longev       Date:  2020-09-08       Impact factor: 6.543

Review 7.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018

8.  NRF2 as a Therapeutic Target in Neurodegenerative Diseases.

Authors:  Mikah S Brandes; Nora E Gray
Journal:  ASN Neuro       Date:  2020 Jan-Dec       Impact factor: 4.146

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.